PacBio and DNAstack Collaborate on Global HiFi Genome Network Hub

Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, announced a collaboration with DNAstack to launch the world’s first global federated dataset of HiFi whole genome sequencing data. Through the HiFi Solves Global Consortium, the initiative enables researchers to securely analyze harmonized genomic datasets across institutions worldwide without centralizing sensitive patient data, a model designed to accelerate rare disease research while maintaining strict data privacy compliance.

For investors, the partnership highlights PacBio’s push to extend the reach of its high-accuracy HiFi sequencing beyond individual labs into large-scale, international research networks.

More on the Collaboration

Under the collaboration, DNAstack is likely to provide the secure, cloud-enabled federated infrastructure that allows participating institutions to connect their PacBio HiFi whole genome sequencing data within a shared network, without transferring or centralizing protected datasets. Researchers can run queries across harmonized genomic and phenotypic data hosted locally at each institution, enabling cross-border analysis while preserving data sovereignty and complying with regional privacy regulations. This federated architecture reduces regulatory friction and removes one of the biggest barriers to large-scale genomic collaboration: the need to physically move sensitive patient data.

The HiFi Solves Global Consortium has grown to nearly 30 clinical and research institutions across 15 countries, collectively connecting or committing more than 10,000 HiFi whole genome sequences. By increasing cohort size and diversity, the collaboration enhances statistical power for rare disease studies, improves interpretation of complex variants such as structural variations and paralogous gene regions, and streamlines workflows that might otherwise require multiple complementary technologies. As the network scales, it creates a recurring ecosystem opportunity for PacBio’s HiFi platform in clinical research settings, reinforcing long-term adoption potential in rare disease genomics.

Industry Prospects Favoring PACB

Per a report by Grand View Research, the global long-read sequencing market size was estimated at $538.9 million in 2024 and is projected to reach $1.53 billion by 2030, expanding at a CAGR of 20.12% from 2025 to 2030.

The major factors driving market growth include the increasing prevalence of genetic diseases like cancers and chromosomal disorders.

Other Developments by PACB

In January, PACB announced that its HiFi whole-genome sequencing technology has been adopted as a first-line approach in a major research effort to study Sudden Unexplained Death in Childhood. PacBio also announced a new community-developed method, CiFi. It enables chromosome-scale, haplotype-resolved genome assemblies from a single sequencing run, even when sample material is limited.

Peers Update

Illumina, Inc. ILMN has remained active on the strategic front in early 2026. Illumina recently completed the acquisition of SomaLogic from Standard BioTools for $350 million in upfront cash, with additional earnout potential, expanding Illumina’s presence into proteomics and strengthening its multiomics ecosystem. The transaction enhances Illumina’s ability to integrate genomic and proteomic data, reinforcing its long-term strategy of offering more comprehensive molecular insights across research and clinical markets. Through this move, Illumina continues positioning ILMN as a broader life sciences platform rather than solely a sequencing provider.

In product innovation, Illumina introduced TruPath Genome, a whole genome solution aimed at advancing genetic disease research. The company stated that TruPath Genome delivers high-resolution, highly accurate insights, including improved coverage of hard-to-sequence “dark regions.” By strengthening variant detection and expanding genomic profiling capabilities, Illumina is reinforcing its positioning in clinical and translational research while maintaining its focus on sequencing innovation.

10x Genomics, Inc. TXG most recently reported its fourth quarter and full year 2025 financials, highlighting performance through a challenging macro environment. For the fourth quarter of 2025, 10x Genomics posted revenues of approximately $166 million, with full-year revenues of $642.8 million and a notable increase in cash reserves to over $523 million. The financials showed improved operating and net loss figures compared with prior-year periods, suggesting tighter cost discipline and deeper execution on strategic priorities.

Beyond results, 10x Genomics is expanding partnerships and research initiatives to deepen adoption of its Chromium and Xenium platforms. 10x Genomics has entered collaborations aimed at building AI-ready datasets and advancing single-cell and spatial biology applications in oncology and translational research.

Thermo Fisher Scientific TMO continues to strengthen its position in life sciences tools, diagnostics and laboratory services through steady product innovation and portfolio expansion. Thermo Fisher Scientific is advancing sequencing, analytical and workflow solutions that support biopharma and research customers, while its recurring consumables model provides durable revenue visibility. This balanced strategy keeps TMO well positioned to capitalize on long-term growth in genomics and drug development markets.

Recently, Thermo Fisher Scientific announced a strategic collaboration with NVIDIA to power AI-based solutions and laboratory automation at scale. The effort will leverage the NVIDIA Artificial Intelligence platform alongside TMO’s solutions to progressively increase the automation, accuracy and speed of laboratories.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.

See

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Thermo Fisher Scientific Inc. (TMO): Free Stock Analysis Report

Illumina, Inc. (ILMN): Free Stock Analysis Report

Pacific Biosciences of California, Inc. (PACB): Free Stock Analysis Report

10x Genomics (TXG): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research